TELATELA Bio, Inc.vs its industry peers
A metric-by-metric comparison of TELA Bio, Inc. against Surgical & Medical Instruments & Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TELAThis | $57M#8 | — | — | 0.7x#4 | 15.8%#4 | -2.6%#9 | -42.0%#5 | — | -257.2%#6 | 3#5 | -18.2%#6 | — |
| GUTS | $94M#1 | — | — | — | -100.0%#14 | -105.2%#14 | — | — | — | — | -39.7%#8 | — |
| LNSR | $87M#2 | 35.6x#4 | 5.9x#11 | 1.7x#8 | 12.4%#6 | -9.2%#10 | -47.6%#7 | -230.0%#8 | — | — | -43.8%#9 | — |
| LUNG | $86M#3 | — | 2.2x#8 | 1.0x#5 | 8.0%#8 | 4.2%#7 | -59.3%#8 | -137.8%#6 | -257.0%#5 | 3#5 | 26.1%#1 | — |
| SKIN | $85M#4 | — | 1.5x#7 | 0.3x#1 | -10.0%#10 | 67.4%#3 | -6.9%#3 | -17.1%#3 | — | — | -72.5%#13 | — |
| CVRX | $78M#5 | — | 3.9x#9 | 1.4x#7 | 10.4%#7 | 11.1%#6 | -90.5%#10 | -267.2%#9 | -296.8%#7 | 3#5 | -59.3%#11 | — |
| DRIO | $68M#6 | 1.3x#2 | 1.2x#3 | 3.0x#12 | -17.3%#11 | 2.4%#8 | -163.9%#11 | -75.7%#5 | -41.6%#3 | 3#5 | 2.4%#3 | — |
| SKYA | $65M#7 | — | 0.4x#1 | 320.1x#14 | — | -2938.9%#16 | -132145.5%#14 | -179.6%#7 | -181.9%#4 | — | -81.4%#14 | — |
| TLSIW | $55M#9 | — | 8.5x#12 | 1.2x#6 | 53.4%#2 | -30.6%#12 | -59.7%#9 | -598.9%#11 | — | 5#4 | -61.7%#12 | — |
| MDAI | $53M#10 | — | — | 2.7x#11 | -33.6%#12 | 50.1%#4 | -43.8%#6 | — | — | 3#5 | -26.7%#7 | — |
| SRTS | $51M#11 | — | 1.4x#5 | 1.9x#9 | -34.3%#13 | -216.1%#15 | -37.5%#4 | -20.9%#4 | — | — | 0.3%#4 | — |
| NEPH | $48M#12 | 27.6x#3 | 5.7x#10 | 2.6x#10 | 32.7%#3 | 1513.5%#1 | 6.1%#1 | 14.3%#1 | 26.8%#1 | 7#1 | 2.7%#2 | — |
| AMIX | $4M#15 | — | 1.3x#4 | — | — | -46.5%#13 | — | -528.6%#10 | -743.5%#10 | — | -82.7%#15 | — |
| XTNT | $45M#13 | — | 1.1x#2 | 0.3x#2 | 14.2%#5 | 130.2%#2 | 5.4%#2 | 0.0%#2 | 5.0%#2 | 7#1 | -49.2%#10 | — |
| XAIR | $3M#16 | 0.2x#1 | 1.5x#6 | 0.4x#3 | 107.3%#1 | 28.7%#5 | -378.2%#12 | -1664.9%#13 | -347.6%#8 | 7#1 | -93.2%#16 | — |
| PETV | $39M#14 | — | 28.5x#13 | 33.9x#13 | 0.8%#9 | -24.7%#11 | -793.9%#13 | -772.3%#12 | -647.5%#9 | — | -4.7%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice